March 03, 2025 02:54 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Crucial to have Trump’s support, says Zelenskyy a day after fiery White House exchange | 'We're looking for peace, Zelenskyy wants Russia-Ukraine war to continue': Donald Trump after White House public spat | Volodymyr Zelenskyy refuses to apologise to Donald Trump after public spat over Russia-Ukraine war | 'Make a deal or we are out': Donald Trump tells Volodymyr Zelenskyy at White House | Himachal govt seeks fund from temple to support welfare schemes, BJP calls move 'shocking' | Injustice to opposition MLAs: Atishi writes to Delhi Assembly Speaker on suspension of 21 AAP lawmakers | We will leave for US tomorrow: Father of Indian student Neelam Shinde after urgent visa grant | 'Not joining BJP or floating any party': Abhishek Banerjee dismisses rumours of his split from TMC | Pune bus rape accused arrested after 75-hour manhunt | Finance Secretary Tuhin Kanta Pandey appointed as new SEBI chief

Philippines healthcare providers administer vaccine approved for prevention of Dengue

| | Feb 23, 2016, at 05:00 am
Kolkata/Lyon, Feb 22 (IBNS): Sanofi Pasteur, the vaccines division of Sanofi, announced on Monday that vaccinations with Dengvaxia have commenced in the Philippines following official receipt of the first shipment of the vaccine earlier this month.
Dengvaxia, a tetravalent dengue vaccine, was approved in the Philippines on 22 December 2015 for the prevention of disease caused by all four Dengue types in individuals from 9-45 years of age living in endemic areas. 
 
The vaccine is administered in three doses given over a one-year period. Asia bears 70% of dengue fever burden globally with an estimated 67 million people being sickened by the disease annually. 
 
In the Philippines alone, over 110,000 people on average get Dengue every year. Asian endemic countries spend an estimated 6.5 billion USD annually in both direct medical and indirect costs due to Dengue.
 
“This is truly a great moment in the history of vaccinology,” states Guillaume Leroy, Vice-President of Dengue Vaccine, Sanofi Pasteur. “Dengvaxia’s availability for administration by healthcare providers in the Philippines, to be followed closely by the initiation of a public sector immunization program in the country is a landmark event for global Dengue prevention and a great achievement for the people of the Philippines.”
 
Medical Societies in the Philippines held a media event in Manila earlier this month to welcome receipt of the first shipment of Dengvaxia to the country.
 
In attendance, Dr. Rose Capeding, chief of the Research Institute for Tropical Medicine’s department of microbiology, noted that the Philippines participated in all three phases of the clinical development of the vaccine and that healthcare providers there were delighted to be able to begin vaccinating against dengue, which continues to pose a major public health threat to the nation.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.